Previous 10 |
home / stock / nnbxf / nnbxf news
Nanobiotix S.A. (NBTX) Q3 2022 Earnings Call Transcript November 10, 2022 08:00 AM ET Company Participants Kate Mcneil - Senior Vice President, Investor Relations Laurent Levy - Co-Founder & Chief Executive Officer Bart Van Rhijn - Chief Financial Officer ...
Nanobiotix S.A (NBTX) Q2 2022 Earnings Conference Call September 29, 2022, 08:00 AM ET Company Participants Laurent Levy - Co-Founder, CEO Bart Van Rhijn - CFO Kate McNeil - IR Conference Call Participants Jon Miller - Evercore Suzanne van Voorthu...
Nanobiotix S.A. (NBTX) Q1 2022 Earnings Conference Call May 19, 2022 8:00 AM ET Company Participants Kate McNeil – Senior Vice President, Investor Relations Laurent Levy – Co-Founder and Chief Executive Officer Bart Van Rhijn – Chief Financial Officer Conference Call Part...
Nanobiotix S.A. (NBTX) Q4 2021 Earnings Conference Call March 31, 2022 08:00 AM ET Company Participants Kate McNeil - Senior Vice President, Investor Relations Laurent Levy - Co-Founder & Chief Executive Officer Bart Van Rhijn - Chief Financial Officer Conference Call Participants Jonatha...
Nanobiotix S.A. ( OTC:NNBXF ) : 1H GAAP EPS of -€0.91. More news on: Nanobiotix S.A., Earnings news and commentary, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
PARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities...
Data show favorable safety and feasibility in 68 heavily pre-treated patients with R/M-HNSCC (Intention-to-Treat population; “ITT”) who received RT-activated NBTXR3 followed by anti-PD-1 as a second-or-later line treatment 48% ORR in evaluable anti-PD-1 naïve patients (n=25...
New data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or metastatic head and neck cancer (n=68) to be presented by Coordinating Investigator Colette Shen, MD, PhD, a...